{"id":"W4400029468","doi":"10.1016/j.annonc.2024.05.541","title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System; McGill University","funders":"Daiichi Sankyo Europe; Janssen Research and Development; Genentech; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; MacroGenics; Plexxikon; BeiGene; Mirati Therapeutics; Yuhan; Mersana Therapeutics; PharmaMar; LAM Therapeutics; Astex Pharmaceuticals; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; LG Chem; Regeneron Pharmaceuticals; Sanofi; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Osimertinib; Oncology; Lung cancer; Internal medicine; Mutant; Disease; Cancer research; Cancer; Epidermal growth factor receptor; Genetics; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001690133,0.00136245,0.002851837,0.0005919799,0.000413115,0.001571464,0.0009231349,0.001011795,0.004959388],"category_scores_gemma":[0.002099019,0.0006242849,0.006929401,0.0006473412,0.0007030389,0.001262958,0.0006191655,0.0034603,0.001065363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001376269,"about_ca_system_score_gemma":0.001360205,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002180543,"about_ca_topic_score_gemma":0.006224191,"domain_scores_codex":[0.9989221,0.0004385434,0.00007685171,0.0002431257,0.00009498657,0.0002243647],"domain_scores_gemma":[0.9987348,0.0003556555,0.0003020373,0.0001466317,0.0001015171,0.0003593047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.931488,0.003377282,0.0189866,0.0009140167,0.01511131,0.0001505715,0.00007749432,0.001178833,0.003639867,0.0001794896,0.002517609,0.02237903],"study_design_scores_gemma":[0.6321712,0.1478555,0.1489116,0.000427212,0.05318264,0.0007735132,0.000377892,0.004536505,0.003217798,0.001363347,0.007023189,0.0001596095],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890695,0.004915121,0.0003045636,0.0003914128,0.0002279832,0.000458985,0.002683213,0.00005236062,0.001896922],"genre_scores_gemma":[0.9916207,0.001651469,0.000398309,0.0006033944,0.0002391245,0.0004141259,0.003302257,0.0000296291,0.001741014],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004959388,"threshold_uncertainty_score":0.01659077,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02074879466258383,"score_gpt":0.3645783786250641,"score_spread":0.3438295839624803,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}